What's in Centre Leon Berard's pipeline?

Centre Leon Berard has 26 drugs in our index: 2 marketed, 0 filed, 8 in Phase 3, 11 in Phase 2, 5 in Phase 1.

Which companies overlap with Centre Leon Berard's portfolio?

Top competitors by shared drug class: AstraZeneca, Jiangsu HengRui Medicine Co., Ltd., GERCOR - Multidisciplinary Oncology Cooperative Group, Pfizer, Akeso.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centre-leon-berard.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Centre Leon Berard — Portfolio Competitive Intelligence Brief

Centre Leon Berard pipeline: 2 marketed, 0 filed, 8 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 8 Phase 3 11 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Firmagon	Firmagon	marketed		Gonadotropin-releasing hormone receptor	Oncology
VEC	VEC	marketed	Therapeutic cancer vaccine		Oncology
BRN01	BRN01	phase 3	CDK4/6 inhibitor	CDK4/6	Oncology
cicaderma + simple hygiene rules	cicaderma + simple hygiene rules	phase 3	Topical treatment		Dermatology
interruption of Glivec®	interruption of Glivec®	phase 3	tyrosine kinase inhibitor	BCR-ABL, c-KIT, PDGFR	Oncology
Pazopanib Oral Tablet [Votrient]	Pazopanib Oral Tablet [Votrient]	phase 3	tyrosine kinase inhibitor	VEGFR, PDGFR, c-KIT	Oncology
Vesanoid	Vesanoid	phase 3			Other
Placebo of AFATINIB	Placebo of AFATINIB	phase 3
Imatinib maintenance	Imatinib maintenance	phase 3	Tyrosine kinase inhibitor	BCR-ABL	Oncology
Cocculine®	Cocculine®	phase 3			Gastroenterology / Symptom Management

Therapeutic area mix

Oncology · 10
Dermatology · 1
Gastroenterology / Symptom Management · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
GERCOR - Multidisciplinary Oncology Cooperative Group · 3 shared drug classes
Pfizer · 3 shared drug classes
Akeso · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Chinese Academy of Medical Sciences · 2 shared drug classes
Air Force Military Medical University, China · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Centre Leon Berard:

Cite this brief

Drug Landscape (2026). Centre Leon Berard — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-leon-berard. Accessed 2026-05-14.